Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Lubor Goláň, Özlem Göker-Alpan, Myrl Holida, Ikka Kantola, Mariusz Kłopotowski, Johanna Kuusisto, Aleš Linhart, Jacek Musiał, Kathy Nicholls, Derlis Gonzalez Rodríguez, Reena Sharma, Bojan Vujkovac, Peter Chang, Anna WijatykDrug 2015 · DOI

Abstract

No efficacy or safety differences were found when the approved EOW dosage of agalsidase alfa was increased to weekly administration. Exploratory analyses for 0.4 mg/kg weekly showed similar results.
BibTeX
@inproceedings{golan2015evaluation,
  author = {Lubor Goláň and Özlem Göker-Alpan and Myrl Holida and Ikka Kantola and Mariusz Kłopotowski and Johanna Kuusisto and Aleš Linhart and Jacek Musiał and Kathy Nicholls and Derlis Gonzalez Rodríguez and Reena Sharma and Bojan Vujkovac and Peter Chang and Anna Wijatyk},
  title = {{Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease}},
  booktitle = {Drug},
  year = {2015},
  doi = {10.2147/dddt.s80928},
}

Loading related content...

Figure